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A b s t r a c t
Measurement o f  IgA and IgM  in cerebrospinal flu id  
(CSF) can be useful in the diagnosis o f  multiple 
sclerosis and other central nervous system disorders. 
The Dade Behring (Deerfield, IL) N  Latex IgA and N  
Latex IgM  tests on the BN II  System and Beckman 
Coulter (Brea, CA) low-concentration IgA and IgM  
tests on the IMMAGE Immunochemistry System were 
evaluated fo r  linearity, imprecision, method 
comparison, and reference interval verification. Both 
IgA methods were linear from  1.4 to at least 50 mg/L. 
Both IgM  methods were linear from  0.14 to more than 6 
mg/L. The total imprecision o f  the B N  II  IgA and IgM  
methods and the IMMAGE IgA method was less than 
10%. The imprecision o f  the IMMAGE IgM  method was 
10.2% at 0.49 mg/L and less than 5% at higher IgM  
concentrations. M ethod comparison studies indicated 
that IgA and IgM  methods on both instruments showed  
good comparability. Reference interval studies 
demonstrated that both methods had similar reference 
intervals that agreed with published values o f  less than 
6 mg/L fo r  IgA and less than 1.3 mg/L fo r  IgM.
Methods fo r  quantifying IgA and IgM  in CSF on the BN  
II  and IMMAGE nephelometers perform well and give 
comparable results.
One of the first reports describing the determination of 
cerebrospinal fluid (CSF) proteins, including albumin, IgG, 
IgA, and IgM, by immunonephelometry appeared almost a 
quarter century ago.1 The simultaneous measurement of 
albumin and IgG in CSF and serum samples has a routine 
role in the diagnosis of multiple sclerosis, and the quantita­
tive determination of CSF IgM to show intrathecal produc­
tion of IgM is an optional test for the diagnosis of multiple 
sclerosis.2 There are a number of situations in which CSF 
IgG measurements alone are not adequate and quantifica­
tion of CSF IgA or IgM is useful. The quantitative determi­
nation of CSF IgA is of little value in the diagnosis of 
multiple sclerosis; however, strong intrathecal production of 
IgA may imply a different diagnosis.3 Intrathecal IgA 
production is the most sensitive CSF parameter for cerebral 
adrenoleukodystrophy and is not seen in patients with 
adrenomyeloneuropathy.4 An intrathecal IgA response can 
indicate a bacterial origin with a response rate of nearly 
90% in neurotuberculosis and can provide information 
about a brain abscess.3 Intrathecal production of IgM can be 
seen in acute and chronic diseases, including neuroborre- 
lio s is , mumps m en in gitis, and parenchym atous 
neurosyphilis.3 Detection of an IgM response alone is not 
very useful but in combination with other CSF data can 
contribute to typical patterns seen in neuroborreliosis, 
mumps meningitis, or non-Hodgkin lymphoma.
It still can be difficult to find automated methods with 
sufficient sensitivity for accurate determinations of IgA and 
IgM in CSF.5 This study was conducted to evaluate the 
current performance characteristics of immunonephelometric 
assays for CSF IgA and IgM from 2 vendors.
©American Society for Clinical Pathology Am J Clin Pathol 2003;119:689-693 689
DOI. 10.1309/ATLW4XBFT135NC56
Owen and R oberts / IgA anp IgM in Cfrfbrospinal Fi.uip by Nephfi.omftry
M a t e r i a l s  a n d  M e t h o d s
Low-concentration IgA and IgM reagent kits and CSF 
protein calibrators were used on an IMMAGE Immunochem- 
istry System (Beckman Coulter, Brea, CA) in accordance 
with the manufacturer’s instructions. N Latex IgA and IgM 
reagents were used on a BN II System (Dade Behring, Deer­
field, IL) in accordance with the manufacturer’s instructions. 
The N Latex IgM method is not available for sale in the 
United States. The reagents from both vendors use particles to 
enhance assay performance and facilitate measurement of the 
low concentrations of IgA and IgM normally present in CSF.
Linearity studies were performed using 2 pools of CSF 
patient samples, one with a high concentration of IgA or IgM 
and one with a low concentration, and making dilutions of the 
high pool with the low pool. Multiple surplus CSF samples 
containing low, medium, and high concentrations of IgA and 
IgM were pooled for use in the imprecision studies. Each pool 
was analyzed in duplicate in each of 2 runs performed daily 
for 5 days for a total of 20 replicates. Different pools were 
used on the BN II and IMMAGE analyzers, and, therefore, the 
mean values for each pool are substantially different.
For method comparison studies, CSF samples were 
selected from those that had been submitted to the clinical 
laboratory for immunoglobulin and albumin analyses. For 
the reference interval study, CSF samples that had been 
submitted to the clinical laboratory for testing to diagnose 
multiple sclerosis and that met the following criteria of 
normality were selected: (1) no oligoclonal bands detected 
by isoelectric focusing and silver staining, (2) normal 
concentrations o f IgG and albumin and a normal
IgG/albumin ratio, and (3) normal albumin and IgG indices. 
For reference interval studies, a total of 82 samples were 
used with 21 from male subjects ranging in age from 14 to 
83 years and 61 from female subjects ranging from 9 to 82 
years. The median age of all subjects was 43 years. Samples 
were stored at -70°C until analysis. Approval of the institu­
tional review board o f the University o f Utah Health 
Sciences Center, Salt Lake City, was obtained for all studies 
in which samples from human subjects were used.
EP Evaluator Release 4 software (David G. Rhoads Asso­
ciates, Kennett Square, PA) was used for complex imprecision 
calculations, Deming regression analysis, calculation of r and 
Sy/x, linearity assessment, and reference interval estimation. 
Reference intervals were determined nonparametrically using 
the Harrell-Davis approach in this software.
R e s u l t s
The linearity of each method was assessed. The BN II 
IgA method was linear from 1.4 to 67.4 mg/L with a 
maximum deviation from a mean recovery of 100% of 7.7%. 
The BN II IgM method was linear from 0.14 to 9.05 mg/L 
with a maximum deviation from a mean recovery of 100% of 
7.4%. The IMMAGE IgA method was linear from 1.4 to 
50.2 mg/L with a maximum deviation from a mean recovery 
of 100% of 6.3%. The IMMAGE IgM method was linear 
from 0.30 to 6.73 mg/L with a maximum deviation from a 
mean recovery of 100% of 9.4%.
The imprecision data for each method are summarized in 
ITable 11. The imprecision of the BN II and IMMAGE CSF
■Table 1I
Summary of Imprecision Study Results
Coefficient of Variation (%)
Instrument*/Pool No. Mean (mg/L) Within Run Between Run Between Day Total
BN ii
1 2.33 5.6 6.0 0.0 8.2
2 8.61 3.5 2.7 0.8 4.5
3 37.85 2.3 2.1 0.0 3.1
IMMAGE
1A 2.09 4.8 6.6 4.7 9.4
2A 7.00 1.9 4.4 0.9 4.9
3A 24.1 2.1 2.0 3.5 4.6
BN ii
1 0.32 4.7 0.0 3.1 5.6
2 2.80 3.0 0.0 0.6 3.0
3 6.91 2.9 1.2 0.0 3.2
IMMAGE
1A 0.49 8.0 6.3 0.0 10.2
2A 2.54 1.4 1.4 1.3 2.4
3A 5.50 3.7 0.0 2.8 4.7
* For manufacturer information, see the text.
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IgA assays was comparable with total coefficients of variation 
of less than 10%, even at the lowest concentration of pooled 
patient material. In contrast, the BN II CSF IgM assay was 
considerably more precise than the IMMAGE CSF IgM assay 
at the lowest concentration of control material assessed that
was within the reference interval of both assays. At concentra­
tions of control materials that were above the upper limit of the 
reference interval, the 2 assays had comparable imprecision.
Method comparison studies for CSF IgA and CSF IgM 
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IFigure 1I Results of cerebrospinal fluid method comparison studies. A, Analysis of 81 sam ples for IgA by both methods. Deming 
regression analysis of all data points gave a slope of 0.99 ± 0.03, an intercept of 0.35 ± 0.20, Sy/x = 0.62, and r=  0.991. B, The 
mean difference is -0.31 mg/L, and 2 SD is 1.24 mg/L. C, Analysis of 77 samples for IgM by both methods. Deming regression analysis 
of all data points gave a slope of 0.96 ± 0.04, an intercept of 0.03 ± 0.05, Sy/x = 0.14, and r=  0.985. D, The mean difference is 0.01 mg/L, 
and 2 SD is 0.30 mg/L. A and C, Solid lines indicate the Deming regression lines; dashed lines indicate x = y. B and D, Solid lines indicate 
the mean differences; dashed lines indicate 2 SD from the means in Bland-Altman analyses. For manufacturer information, see the text.
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methods compared very well by Deming regression with a 
slope of 0.99 and a correlation coefficient of 0.991. The IgM 
methods also gave an acceptable comparison with a slope of
0.96 and a correlation coefficient of 0.985. Bland-Altman 
plots revealed an increased degree of scatter for IgA at 
concentrations below 10 mg/L and for IgM at concentrations 
of 2 mg/L.
The nonparametric reference intervals determined in this 
study were 0.7 to 7.0 and 0.9 to 7.1 mg/L for CSF IgA for 
the BN II and IMMAGE methods, respectively. Similarly, 
nonparametric reference intervals were less than 1.2 and less 
than 1.1 mg/L for CSF IgM determined by the BN II and 
IMMAGE methods, respectively.
D i s c u s s i o n
Both methods were highly linear across appropriate 
CSF immunoglobulin concentrations. All methods showed 
acceptable imprecision except for the IMMAGE IgM, which 
showed borderline imprecision at CSF IgM concentrations 
below the upper limit of the reference interval. Method 
comparison studies demonstrated good comparability for 
both sets of methods. This indicates a high degree of calibra­
tion standardization.
One area that requires further work is the reference 
intervals. The reference intervals in the package inserts for 
the 4 assays were all taken from the literature. The reference 
intervals for the IMMAGE CSF IgA and IgM were less than
2.0 mg/L. The reference cited (Burtis and Ashwood6) in the 
IMMAGE package insert has 2 different reference intervals 
printed in different sections. On page 517, reference intervals 
for both IgA and IgM are listed as less than 2 mg/L when 
measured by radioimmunoassay (RIA).6 On page 1820, age- 
specific parametric reference intervals for IgA determined by 
RIA are listed with an upper limit of 2.3 mg/L, and on page 
1821, age-specific parametric reference intervals for IgM by 
RIA are listed with an upper limit of 0.27 mg/L.6 The N 
Latex IgA package insert for CSF lists upper limits of the 
reference interval of 6 and 5 mg/L based on 2 references.7,8 
Similarly, the N Latex IgM package insert for CSF lists 
upper limits of the reference interval of 1.3 and 2 mg/L 
based on the same 2 references.7,8 A review of the literature 
revealed 1 additional reference interval study performed for 
CSF IgM using an enzyme-linked immunosorbent assay 
method in which the upper reference limit, calculated as the
0.95 fractile, was 0.36 mg/L.9
The reference intervals determined in the present study 
of 0.7 to 7.0 and 0.9 to 7.1 mg/L for CSF IgA for the BN II 
and IMMAGE methods, respectively, agree best with an 
upper limit o f less than 6 mg/L indicated in the BN II 
package insert and taken from a single reference.7 Similarly,
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the reference intervals of less than 1.2 and less than 1.1 mg/L 
for CSF IgM determined for the BN II and IMMAGE 
methods, respectively, agree best with an upper limit of less 
than 1.3 mg/L indicated in the N Latex IgM package insert 
and taken from the same reference.7 The use of CSF-serum 
quotients for immunoglobulins reduces the influence of indi­
vidual biologic variability in plasma concentrations on the 
interpretation of CSF data and may be more useful than the 
CSF concentrations alone.10,11 It is noteworthy that the refer­
ence intervals for both CSF IgA and IgM are virtually iden­
tical for both nephelometers, although the reference intervals 
published in the package inserts do not reflect this close 
agreement. Additional studies on appropriate clinical deci­
sion thresholds and the use of these assays for the diagnosis 
and monitoring of multiple sclerosis are warranted.
C o n c l u s i o n s
Methods for quantifying IgA and IgM in CSF on the 
BN II and IMMAGE nephelometers perform well and give 
comparable results. These results should facilitate automated 
measurements of these analytes on a more routine basis. 
Information about intrathecal production of IgA and IgM can 
be useful in the diagnosis of a number of central nervous 
system disorders.
From the 1A RU P  Institute fo r  Clinical & E xperim ental Pathology, 
Salt Lake City, UT; and the 2D epartm ent o f  Pathology, University  
o f  Utah H ealth  Sciences Center, Salt Lake City.
Supported  by Dade B ehring and  the A R U P  Institute fo r  
Clinical & E xperim ental Pathology. D ade B ehring also provided  
the investigational-use-only reagents.
Address reprint requests to D r Roberts: c/o ARU P  
Laboratories, 500  Chipeta Way, Salt Lake City, U T 84108.
R e f e r e n c e s
1. Kjellin KG, Hallanger LB. Determination of CSF proteins by 
a simple and rapid immunonephelometric method. J Neurol. 
1980;223:35-42.
2. AnderssonM, Alvarez'Cermeno J, Bernardi G, et al. Cerebro­
spinal fluid in tbe diagnosis of multiple sclerosis: a consensus 
report. J Neurol Neurosurg Psychiatry. 1994;57:897-902.
3. Reiber J, Peter JB. Cerebrospinal fluid analysis: disease-related 
data patterns and evaluation programs. ] Neurol Sci. 
2001;184:101-122.
4. Korenke GC, Reiber H, Hunneman DH, et al. Intrathecal 
IgA synthesis in X-linked cerebral adrenoleukodystrophy.
J Chilcl Neurol. 1997;12:314-320.
5. Reiber H. External quality assessment in clinical 
neurochemistry: survey of analysis for cerebrospinal fluid 
(CSF) protein based on CSF/serum quotients. Clin Chem. 
1995;41:256-263.
©American Society for Clinical Pathology
Immunopathology / Originai Artici f.
6. Rurtis CA, Ash wood ER, eds. Ti etz Textbook of Clinical 
Chemistry. 3rd ed. Philadelphia, PA: Saunders; 1999.
7- Reiber H. Aktuelle methoden der liquoranalytik. luib Med. 
1988;12:101-109.
8. Raudner S, Rienvenu J, Rlirup-Jensen S, et al. The Certification 
of a Matrix Reference Material for Immunochemical Measurement 
of 14 lltiman Senim Proteins: CRM 470. Rrussels, Relgium: 
Community Rureau of Reference, Commission of the 
European Communities; 1993.
9. Rlennow K, Skoog 1, Wallin A, et al. Immunoglobulin M in 
cerebrospinal fluid: reference values derived from 111 healthy 
individuals 18-88 years of age. Eur Neurol. 1996;36:201-205.
10. Ganrot K, Laurell C-R. Measurement of IgG and albumin 
content of cerebrospinal fluid and its interpretation. Clin 
Chem. 1974;20:571-573.
11. Reiber H. The discrimination between different blood-CSF 
barrier dysfunctions and inflammatory reactions of the CNS 
by a recent evaluation graph for the protein profile of 
cerebrospinal fluid. J Neurol. 1980;224:89-99.
© American Society for Clinical Pathology Am J Clin Pathol 2003; 119:689-693 6  93
DOI- 10 1309/ATLW4XBFT135NC56
